![]() |
Volumn 39, Issue 5, 2011, Pages 325-327
|
Current regulatory and scientific considerations for approving biosimilars in Iran
|
Author keywords
Biosimilars guideline; Follow on biologics; Iran; Similar biological medicinal products; Subsequent entry biologics; WHO
|
Indexed keywords
BIOLOGICAL PRODUCT;
GENERIC DRUG;
MONOCLONAL ANTIBODY;
RECOMBINANT PROTEIN;
RIBOSOME DNA;
ARTICLE;
BIOASSAY;
BIOTECHNOLOGY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INFORMATION;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG PACKAGING;
DRUG QUALITY;
DRUG RESEARCH;
DRUG SAFETY;
IRAN;
LICENCE;
PATENT;
PHYSICAL CHEMISTRY;
PRACTICE GUIDELINE;
PREDICTION;
PRIORITY JOURNAL;
RELIABILITY;
WORLD HEALTH ORGANIZATION;
ANIMALS;
DRUG APPROVAL;
DRUG EVALUATION;
DRUG EVALUATION, PRECLINICAL;
DRUG INDUSTRY;
DRUG TOXICITY;
GUIDELINES AS TOPIC;
HUMANS;
IRAN;
PHARMACEUTICAL PREPARATIONS;
WORLD HEALTH ORGANIZATION;
ANIMALIA;
|
EID: 80053573760
PISSN: 10451056
EISSN: 10958320
Source Type: Journal
DOI: 10.1016/j.biologicals.2011.06.019 Document Type: Article |
Times cited : (6)
|
References (7)
|